Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of lung cancer called non-squamous non-small cell lung cancer with an EGFR mutation (either exon 19 deletion or L858R).
- Your cancer must have spread to your brain, and you should have at least one brain spot that is 5 mm or larger, but symptoms must be controlled or easily managed.
- You cannot have had any prior chemotherapy or targeted therapy for advanced lung cancer (if you had treatment for early-stage cancer, it must have been more than 6 months ago).
- Your major organs (heart, kidneys, liver, blood cells) must work well enough based on blood tests and heart scans.
- You must not have had whole-brain radiation therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.